基于网络药理分析和实验验证补阳还五汤通过抑制PI3K/AKT/FOXO1通路保护缺氧-复氧损伤后的内皮细胞

时研; 周悦; 关卿; 温庆思; 孙玉; 闫泽文; 李煜烨; 朱清楠; 林洪丽; 王大鹏

0
0
浏览
下载

摘要
关键词
基金信息
论文图表
同行评议
相关论文
评论

Network-based analysis and experimental validation explored Bu-Yang-Huan-Wu-Tang protects endothelial cells after hypoxia-reoxygenation injury by inhibiting the PI3K/AKT/FOXO1 pathway

首发时间：2024-03-06

Shi Yan ^{1
2
3}
Shi Yan(1999-),female, nephropathology
Zhou Yue Guan Qing Wen Qingsi Sun Yu Yan Zewen Li Yuye Zhu Qingnan Lin Hongli Wang Dapeng
Wang Dapeng(1978-),Male, Chief Physician, Integrated Chinese and Western Medicine Chronic Kidney Disease

1、College of Integrative Medicine, Dalian Medical University, Dalian 116041
2、 Department of Nephrology, The First Affiliated Hospital of Dalian Medical University, Dalian 116011
3、Department of Nephrology, The First Affiliated Hospital of Dalian Medical University, Dalian 116011

Abstract：Purpose: To explore the drug targets and potential mechanisms of Bu-Yang-Huan-Wu-Tang (BYHWT) in the treatment of acute kidney injury (AKI) through network pharmacology and experimental validation. Methods: A network-based analysis research approach was used to predict the main active ingredients, targets of action and potential signaling pathways of BYHWT for AKI treatment. The protective effect of BYHWT on human umbilical vein endothelial cells (HUVEC) was verified by detecting the PI3K/AKT/FOXO1 signaling pathway and related factors through in vitro experiments. Results：A total of 124 active components of BYHWT were screened, with 444 action targets, 1,708 AKI disease-related target genes, and 210 targets at the intersection of components and diseases were obtained. Through GO and KEGG enrichment analysis, we obtained 219 signaling pathways of BYHWT for the treatment of AKI, and screened the top 10 pathways with the highest degree of enrichment, which involved the PI3K-AKT signaling pathway, and the experimental validation results showed that BYHWT-containing serum increased the expression of p-PI3K, p-AKT, and p-FOXO1, and increased the phosphorylation of FOXO1, and decreased the expression of FOXO1 expression. Conclusion: BYHWT may play a role in ameliorating endothelial cell apoptosis and protecting injured endothelial cells by regulating the PI3K/AKT/FOXO1 pathway.

keywords： AKI Network-based analysis BYHWT hypoxia-reoxygenation HUVEC network analysis

点击查看论文中文信息

基于网络药理分析和实验验证补阳还五汤通过抑制PI3K/AKT/FOXO1通路保护缺氧-复氧损伤后的内皮细胞

时研 ^{1
2}
Shi Yan(1999-),female, nephropathology
周悦关卿 温庆思 孙玉 闫泽文 李煜烨 朱清楠 林洪丽 王大鹏 ²
Wang Dapeng(1978-),Male, Chief Physician, Integrated Chinese and Western Medicine Chronic Kidney Disease

1、大连医科大学中西医结合学院，大连 116041
2、大连医科大学附属第一医院肾内科，大连 116011

摘要：目的：通过网络药理学和实验验证，探讨BYHWT在急性肾损伤（AKI）治疗中的药物靶点和潜在机制。方法：采用网络药理学研究方法预测BYHWT治疗AKI的主要活性成分、作用靶点和潜在信号通路。通过体外实验检测PI3K/AKT/FOXO1信号通路及相关因子，验证BYHWT对脐静脉内皮细胞（HUVEC）的保护作用。结果：筛选得到BYHWT活性成分共124个，作用靶点444个，AKI疾病相关靶基因1708个，得到成分与疾病交集靶点210个。通过GO和KEGG富集分析得到BYHWT治疗AKI的219条信号通路，筛选其中富集程度最高的前10条通路，结果涉及PI3K-AKT信号通路。体外实验验证结果，BYHWT含药血清能增加p-PI3K、p-AKT、p-FOXO1的表达，增加FOXO1磷酸化，降低FOXO1表达。结论：BYHWT可能通过调控PI3K/AKT/FOXO1通路发挥改善内皮细胞的凋亡，保护损伤的内皮细胞。

关键词：急性肾损伤; 网络药理学; 补阳还五汤; 缺氧复氧; 人脐静脉内皮细胞; 网络分析

基金：

论文图表：

引用

导出参考文献

.txt

.ris

.doc

Shi Yan,Zhou Yue,Guan Qing,et al. Network-based analysis and experimental validation explored Bu-Yang-Huan-Wu-Tang protects endothelial cells after hypoxia-reoxygenation injury by inhibiting the PI3K/AKT/FOXO1 pathway[EB/OL]. Beijing:Sciencepaper Online[2024-03-06]. https://www.paper.edu.cn/releasepaper/content/202403-63.

No.****

同行评议

未申请同行评议

全部评论

0/1000

论文编号	202403-63
论文题目	基于网络药理分析和实验验证补阳还五汤通过抑制PI3K/AKT/FOXO1通路保护缺氧-复氧损伤后的内皮细胞
文献类型
收录期刊	上传封面中文期刊英文期刊期刊名称（中文）期刊名称（英文）年，卷（）上传封面中文专著英文专著书名（中文）书名（英文）出版地出版社出版年上传封面中文译著英文译著书名（中文）书名（英文）出版地出版社出版年上传封面中文论文集英文论文集编者.论文集名称（中文） [c]. 出版地出版社出版年， - 编者.论文集名称（英文） [c]. 出版地出版社出版年，- 上传封面中文文献英文文献期刊名称（中文）期刊名称（英文）日期-- 在线地址http:// 上传封面中文文献英文文献文题（中文）文题（英文）出版地出版社,出版日期-- 上传封面中文文献英文文献文题（中文）文题（英文）出版地出版社,出版日期--
英文作者写法：中外文作者均姓前名后，姓大写，名的第一个字母大写，姓全称写出，名可只写第一个字母，其后不加实心圆点“.”, 作者之间用逗号“，”分隔，最后为实心圆点“.”, 示例1：原姓名写法：Albert Einstein,编入参考文献时写法：Einstein A. 示例2：原姓名写法：李时珍；编入参考文献时写法：LI S Z. 示例3：YELLAND R L,JONES S C,EASTON K S,et al.